PPGN.SW Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 bal. 2024 @ 14:33):

Stats
Dzisiejszy wolumen	2 879.00
Średni wolumen	63 835.00
Kapitalizacja rynkowa	992.38M
EPS	CHF0 ( 2024-03-12 )
Last Dividend	CHF0 ( N/A )
Next Dividend	CHF0 ( N/A )
P/E	-19.67
ATR14	CHF0.0800 (0.27%)

Wolumen Korelacja

Długi: 0.18 (neutral)

Krótki: -0.20 (neutral)

Signal:(46.739) Neutral

PolyPeptide Group AG Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

PolyPeptide Group AG Korelacja - Waluta/Towar

0.80
( moderate )

0.87
( strong )

0.82
( strong )

0.84
( strong )

-0.61
( weak negative )

-0.21
( neutral )

PolyPeptide Group AG Finanse

Annual	2023
Przychody:	CHF320.37M
Zysk brutto:	CHF4.64M (1.45 %)
EPS:	CHF-1.560

FY	2023
Przychody:	CHF320.37M
Zysk brutto:	CHF4.64M (1.45 %)
EPS:	CHF-1.560

FY	2022
Przychody:	CHF280.98M
Zysk brutto:	CHF51.99M (18.50 %)
EPS:	CHF0.240

Financial Reports:

No articles found.

PolyPeptide Group AG

PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.